2023-06-12 17:22:16 ET
Teva Pharmaceutical Industries ( NYSE: TEVA ) said it has agreed to pay $1.41B to settle the State of Kentucky's price-fixing claims against the company.
The Israeli drugmaker said the settlement, which was reached with Kentucky's attorney general's office, was within the estimated provision the company recorded in Q3 2022 for the case.
"The Company is pleased to put Kentucky’s claims behind us, and we believe the amounts included in the settlements to date reflect our position on the allegations against us, which we continue to deny," Teva said in a statement.
Last week, Teva along with Walgreens ( WBA ), CVS ( CVS ) and AbbVie's Allergan division ( ABBV ) agreed to pay $17.3B as part of a national settlement over their alleged roles in the US opioid crisis.
More on Teva: Teva, Walgreens, CVS, AbbVie to pay $17.3B in national opioid settlement
FDA reportedly looking for suppliers to ease methotrexate shortage
Teva Pharmaceutical S&P rating outlook changed to stable from positive
For further details see:
Teva settles price-fixing claims with State of Kentucky for $1.41B